Last reviewed · How we verify
CINRYZE with rHuPH20
At a glance
| Generic name | CINRYZE with rHuPH20 |
|---|---|
| Also known as | C1 esterase inhibitor (human), Recombinant human hyaluronidase |
| Sponsor | Shire |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase (PHASE2)
- Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CINRYZE with rHuPH20 CI brief — competitive landscape report
- CINRYZE with rHuPH20 updates RSS · CI watch RSS
- Shire portfolio CI